Should I buy or sell Nurix Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NRIX shares. View NRIX analyst ratings or view top-rated stocks .

What is Nurix Therapeutics' stock price target for 2024?

6 brokers have issued 1 year price objectives for Nurix Therapeutics' stock. Their NRIX share price targets range from $10.00 to $31.00. On average, they predict the company's stock price to reach $21.33 in the next twelve months. This suggests a possible upside of 48.4% from the stock's current price. View analysts price targets for NRIX or view top-rated stocks among Wall Street analysts .

How have NRIX shares performed in 2024?

Nurix Therapeutics' stock was trading at $10.32 at the start of the year. Since then, NRIX shares have increased by 39.3% and is now trading at $14.38. View the best growth stocks for 2024 here .

When is Nurix Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024. View our NRIX earnings forecast .

How were Nurix Therapeutics' earnings last quarter?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) posted its quarterly earnings data on Thursday, February, 15th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.26. The firm earned $15.16 million during the quarter, compared to analyst estimates of $30.66 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative trailing twelve-month return on equity of 67.08%.

What ETFs hold Nurix Therapeutics' stock?

ETFs with the largest weight of Nurix Therapeutics (NASDAQ:NRIX) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of Nurix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG) , Intel (INTC) , AbbVie (ABBV) , Alibaba Group (BABA) , BigCommerce (BIGC) , Beyond Meat (BYND) , Delta Air Lines (DAL) , DocuSign (DOCU) , Fastly (FSLY) and Fiverr International (FVRR) .

When did Nurix Therapeutics IPO?

Nurix Therapeutics (NRIX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager.

Who are Nurix Therapeutics' major shareholders?

Nurix Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.21%). Insiders that own company stock include Christine Ring , Gwenn Hansen , Houte Hans Van, Pierre Beaurang and Stefani Wolff. View institutional ownership trends .

How do I buy shares of Nurix Therapeutics?

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NRIX

Nurix Therapeutics (NRIX) Stock Price, News & Analysis

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)

Free NRIX Stock Alerts

$14.42

+0.34 (+2.41%)

(As of 01:15 PM ET)

Compare

Today's Range: $13.64
▼
$14.60
50-Day Range: $8.62
▼
$17.48
52-Week Range: $4.22
▼
$18.12

Volume: 306,903 shs
Average Volume: 935,351 shs
Market Capitalization: $708.74 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.33

Get Nurix Therapeutics alerts:

Nurix Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 48.4% Upside
$21.33 Price Target
Short Interest: Bearish
14.18% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.38
Based on 15 Articles This Week
Insider Trading: Selling Shares
$100,256 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.23) to ($3.47) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.58 out of 5 stars

Medical Sector

674th out of 914 stocks

Pharmaceutical Preparations Industry

309th out of 420 stocks

4.4

Analyst's Opinion

Consensus Rating
Nurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Nurix Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
14.18% of the outstanding shares of Nurix Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Nurix Therapeutics has a short interest ratio ("days to cover") of 8.7.
Change versus previous month
Short interest in Nurix Therapeutics has recently increased by 8.74%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Nurix Therapeutics does not currently pay a dividend.
Dividend Growth
Nurix Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NRIX.

1.9

News and Social Media Coverage

News Sentiment
Nurix Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Nurix Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 17 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $100,256.00 in company stock.
Percentage Held by Insiders
Only 7.20% of the stock of Nurix Therapeutics is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Nurix Therapeutics are expected to decrease in the coming year, from ($3.23) to ($3.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nurix Therapeutics is -5.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nurix Therapeutics is -5.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nurix Therapeutics has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)

[Get Your Insights Now]

About Nurix Therapeutics Stock (NASDAQ:NRIX)

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

NRIX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NRIX Stock News Headlines

April 17, 2024 | msn.com

Nurix Therapeutics (NRIX) Price Target Increased by 5.58% to 25.09

April 15, 2024 | msn.com

Nurix Therapeutics (NASDAQ:NRIX) Climbs Higher After Beating Expectations

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

April 15, 2024 | seekingalpha.com

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

April 14, 2024 | americanbankingnews.com

Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Down to $17.21

April 14, 2024 | americanbankingnews.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $20.40 Average PT from Brokerages

April 13, 2024 | americanbankingnews.com

Nurix Therapeutics (NASDAQ:NRIX) PT Raised to $25.00

April 13, 2024 | americanbankingnews.com

Nurix Therapeutics (NASDAQ:NRIX) PT Raised to $23.00 at Royal Bank of Canada

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 12, 2024 | marketwatch.com

Shares of Nurix Therapeutics Down 6% on Plans for Stock Sale

April 12, 2024 | seekingalpha.com

Nurix Therapeutics prices upsized stock offering to raise $175 million

April 12, 2024 | americanbankingnews.com

Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Up Following Analyst Upgrade

April 11, 2024 | markets.businessinsider.com

Nurix Therapeutics Announces $125 Mln Public Stock Offering; Stock Down In After-hours

April 11, 2024 | globenewswire.com

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

April 11, 2024 | globenewswire.com

Nurix Therapeutics Announces Proposed Public Offering

April 10, 2024 | finanznachrichten.de

Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

April 10, 2024 | markets.businessinsider.com

Nurix Therapeutics, Inc. Q1 Loss increases, but beats estimates

April 10, 2024 | finance.yahoo.com

Nurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024

April 10, 2024 | msn.com

NRIX Stock Earnings: Nurix Therapeutics Beats EPS, Misses Revenue for Q1 2024

April 10, 2024 | globenewswire.com

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

April 10, 2024 | americanbankingnews.com

Nurix Therapeutics (NASDAQ:NRIX) Receives "Buy" Rating from Needham & Company LLC

April 10, 2024 | americanbankingnews.com

Nurix Therapeutics (NRIX) Scheduled to Post Quarterly Earnings on Thursday

April 9, 2024 | marketwatch.com

Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration

April 9, 2024 | globenewswire.com

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

April 9, 2024 | globenewswire.com

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

April 3, 2024 | globenewswire.com

Nurix Therapeutics to Participate in Upcoming Investor Conferences

April 2, 2024 | markets.businessinsider.com

Nurix Therapeutics Earns ‘Buy’ Rating on Strong Partnerships and Revenue Potential

See More Headlines

Receive NRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/18/2024
Next Earnings (Estimated): 7/11/2024
Fiscal Year End: 11/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NRIX
CUSIP: N/A
CIK: 1549595
Web: www.nurixtx.com
Phone: 415-660-5320
Fax: N/A
Employees: 284
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.33
High Stock Price Target: $31.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +51.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-143,950,000.00
Net Margins: -178.93%
Pretax Margin: -178.82%
Return on Equity: -67.08%
Return on Assets: -43.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.86
Quick Ratio: 2.86

Sales & Book Value

Annual Sales: $76.99 million
Price / Sales: 8.99
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.43 per share
Price / Book: 4.10

Miscellaneous

Outstanding Shares: 49,150,000
Free Float: 44,334,000
Market Cap: $692.03 million
Optionable: Optionable
Beta: 2.06

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Arthur T. Sands M.D. (Age 62)
Ph.D., CEO, President & Director
Comp: $986.32k
Mr. Johannes Van Houte (Age 58)
Chief Financial Officer
Comp: $681.98k
Dr. Gwenn M. Hansen Ph.D. (Age 53)
Chief Scientific Officer
Comp: $702.75k
Dr. John Kuriyan Ph.D.
Founder & Member of Scientific Advisory Board
Mr. Michael Rapé Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Arthur Weiss M.D.
Ph.D., Founder & Member of Scientific Advisory Board
Rita Kwong
Senior Accounting Manager
Dr. Christine Ring J.D. (Age 59)
Ph.D., Chief Legal Officer, Secretary & Chief Compliance Officer
Comp: $595.83k
Mr. Eric C. Schlezinger J.D. (Age 57)
Chief People Officer
Dr. Jason Kantor Ph.D.
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NRIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Nurix Therapeutics stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NRIX shares.
View NRIX analyst ratings or view top-rated stocks.
What is Nurix Therapeutics' stock price target for 2024?: 6 brokers have issued 1 year price objectives for Nurix Therapeutics' stock. Their NRIX share price targets range from $10.00 to $31.00. On average, they predict the company's stock price to reach $21.33 in the next twelve months. This suggests a possible upside of 48.4% from the stock's current price.
View analysts price targets for NRIX or view top-rated stocks among Wall Street analysts.
How have NRIX shares performed in 2024?: Nurix Therapeutics' stock was trading at $10.32 at the start of the year. Since then, NRIX shares have increased by 39.3% and is now trading at $14.38.
View the best growth stocks for 2024 here.
When is Nurix Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024.
View our NRIX earnings forecast.
How were Nurix Therapeutics' earnings last quarter?: Nurix Therapeutics, Inc. (NASDAQ:NRIX) posted its quarterly earnings data on Thursday, February, 15th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.26. The firm earned $15.16 million during the quarter, compared to analyst estimates of $30.66 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative trailing twelve-month return on equity of 67.08%.
What ETFs hold Nurix Therapeutics' stock?: ETFs with the largest weight of Nurix Therapeutics (NASDAQ:NRIX) stock in their portfolio include ARK Genomic Revolution ETF (ARKG).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Nurix Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND), Delta Air Lines (DAL), DocuSign (DOCU), Fastly (FSLY) and Fiverr International (FVRR).
When did Nurix Therapeutics IPO?: Nurix Therapeutics (NRIX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager.
Who are Nurix Therapeutics' major shareholders?: Nurix Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.21%). Insiders that own company stock include Christine Ring, Gwenn Hansen, Houte Hans Van, Pierre Beaurang and Stefani Wolff.
View institutional ownership trends.
How do I buy shares of Nurix Therapeutics?: Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRIX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial